ICU Medical Q1 revenue and profit beat estimates despite divestiture

ICU Medical

07/05/2026 22:15

Overview

U.S. medical device maker's Q1 revenue beat analyst expectations despite 12% yr/yr decline post-divestiture

Adjusted EPS and adjusted EBITDA for Q1 beat analyst expectations

Company's gross margin rose to 39% from 35% yr/yr, driven by product mix and divestiture

Outlook

Company did not provide specific guidance or outlook for the current quarter or full year

Result Drivers

DIVESTITURE IMPACT - Revenue decline primarily reflects the strategic divestiture of the IV Solutions business in May 2025

PRODUCT LINE PERFORMANCE - Consumables and Infusion Systems posted year-over-year revenue growth, while Vital Care declined due to the IV Solutions divestiture

Company press release: ID:nGNX88Qsk7

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$530.23 mln
$520.48 mln (6 Analysts)
Q1 Adjusted EPS
Beat
$1.97
$1.75 (6 Analysts)
Q1 Adjusted EBITDA
Beat
$98.70 mln
$96.13 mln (6 Analysts)
Q1 Gross Margin
39.00%
Q1 Gross Profit
$206.23 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for ICU Medical Inc is $180.00, about 50.5% above its May 6 closing price of $119.59

The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 19 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)